Comparative Analysis of the Safety and Efficacy of Transcatheter Arterial Chemoembolization and Yttrium-90 Radioembolization in Patients with Unresectable Hepatocellular Carcinoma

Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis

“…After 1,494 studies were excluded, the remaining 49 studies were examined at length. Finally, seven case control studies (23)(24)(25)(26)(27)(28)(29) and one cohort study (30) were eligible for inclusion criteria ( Figure 1). A total of 1,499 patients were included among the eight studies, with 451 patients in the TARE group and 1,048 patients in TACE group.…”

“…Four of the eight studies included in the meta-analysis reported the results of data on hospitalization time days were conducted in USA (24)(25)(26)(27)(28)30), one in China (23), one in Germany combined with Egypt (29). All the studies were published in English.…”

Predictive Role of ERCC1 and XPD Genetic Polymorphisms in Survival of Chinese Non-small Cell Lung Cancer Patients Receiving Chemotherapy

“…The polymorphisms of XPD codon XPD Lys751Gln is reported to be a risk a allele and that patients with Gln allele genotype had a significantly increased risk of developing lung cancer (Kiyohara et al, 2007). Previous studies on the association between XPD Lys751Gln and NSCLC are inconclusive (Lance et al, 2011). The differences in the results of XPD gene polymorphism might be due to country of origin, types of regimen used as first-line chemotherapy, sample sizes, study design and clinical management.…”

Standards of Practice in Transarterial Radioembolization

“…A retrospective cohort comparison of RE (resin or glass microspheres, n = 38) vs. TACE (conventional TACE/drug-eluting bead TACE, n = 35) was published by Lance et al [29]. There were no significant differences between the two cohorts and no significant difference in overall survival between RE and TACE (median 8.0 vs. 10.3 months) cohorts (p = 0 0.33).…”

“…RE is a safe procedure with a lower toxicity than chemoembolization [29,31]. The most common adverse effect is PRS, which occurs in up to 50 % of the patients and may last for about 2 weeks.…”